Advice
in the absence of a submission from the holder of the marketing authorisation
abatacept (Orencia®) is not recommended for use within NHS Scotland.
Indication under review: Treatment of highly active and progressive disease in adult patients with rheumatoid arthritis not previously treated with methotrexate.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting. As a result we cannot recommend its use within NHSScotland.
Download detailed advice58KB (PDF)
Medicine details
- Medicine name:
- abatacept (Orencia)
- SMC ID:
- 1230/17
- Indication:
- Treatment of highly active and progressive disease in adult patients with rheumatoid arthritis not previously treated with methotrexate.
- Pharmaceutical company
- Bristol-Myers Squibb Pharmaceuticals Ltd
- BNF chapter
- Musculoskeletal and joint diseases
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 13 March 2017